• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异源 ChAdOx1-nCoV-19 初免和 BNT162b2 或 mRNA-1273 加强与同源 COVID-19 疫苗方案的免疫原性和反应原性比较。

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.

机构信息

Department of Transplant and Infection Immunology, Saarland University, Homburg, Germany.

Department of Internal Medicine IV, Saarland University, Homburg, Germany.

出版信息

Nat Commun. 2022 Aug 11;13(1):4710. doi: 10.1038/s41467-022-32321-0.

DOI:10.1038/s41467-022-32321-0
PMID:35953492
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9366133/
Abstract

Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and homologous vaccination strategies in a convenience cohort of 331 healthy individuals. All regimens induce immunity to the vaccine antigen. Immunity after vaccination with ChAdOx1-nCoV-19 followed by either BNT162b2 (n = 66) or mRNA-1273 (n = 101) is equivalent to or more pronounced than homologous mRNA-regimens (n = 43 BNT162b2, n = 59 mRNA-1273) or homologous ChAdOx1-nCoV-19 vaccination (n = 62). We note highest levels of spike-specific CD8 T-cells following both heterologous regimens. Among mRNA-containing combinations, spike-specific CD4 T-cell levels in regimens including mRNA-1273 are higher than respective combinations with BNT162b2. Polyfunctional T-cell levels are highest in regimens based on ChAdOx1-nCoV-19-priming. All five regimens are well tolerated with most pronounced reactogenicity upon ChAdOx1-nCoV-19-priming, and ChAdOx1-nCoV-19/mRNA-1273-boosting. In conclusion, we present comparative analyses of immunogenicity and reactogenicity for heterologous vector/mRNA-boosting and homologous mRNA-regimens.

摘要

比较同源和异源 SARS-CoV-2 疫苗方案的免疫原性和反应原性将为优化疫苗策略提供信息。在这里，我们分析了 331 名健康个体的便利队列中异源和同源疫苗方案后的体液和细胞免疫反应。所有方案均诱导疫苗抗原的免疫。用 ChAdOx1-nCoV-19 进行疫苗接种后再接种 BNT162b2（n=66）或 mRNA-1273（n=101）的免疫与同源 mRNA 方案（n=43 BNT162b2，n=59 mRNA-1273）或同源 ChAdOx1-nCoV-19 疫苗接种（n=62）相当或更明显。我们注意到两种异源方案后刺突特异性 CD8 T 细胞水平最高。在含有 mRNA 的组合中，包括 mRNA-1273 的方案中的刺突特异性 CD4 T 细胞水平高于分别与 BNT162b2 的组合。基于 ChAdOx1-nCoV-19 引发的方案中多功能 T 细胞水平最高。所有五种方案均具有良好的耐受性，在 ChAdOx1-nCoV-19 引发和 ChAdOx1-nCoV-19/mRNA-1273 增强时反应原性最明显。总之，我们对异源载体/mRNA 增强和同源 mRNA 方案的免疫原性和反应原性进行了比较分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/40d03a654e4a/41467_2022_32321_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/de097da060eb/41467_2022_32321_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/b0121c8cfc90/41467_2022_32321_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/ce4a784d44cc/41467_2022_32321_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/e1bc4cbab6ee/41467_2022_32321_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/40d03a654e4a/41467_2022_32321_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/de097da060eb/41467_2022_32321_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/b0121c8cfc90/41467_2022_32321_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/ce4a784d44cc/41467_2022_32321_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/e1bc4cbab6ee/41467_2022_32321_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19de/9372164/40d03a654e4a/41467_2022_32321_Fig5_HTML.jpg

相似文献

1
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.异源 ChAdOx1-nCoV-19 初免和 BNT162b2 或 mRNA-1273 加强与同源 COVID-19 疫苗方案的免疫原性和反应原性比较。
Nat Commun. 2022 Aug 11;13(1):4710. doi: 10.1038/s41467-022-32321-0.
2
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.ChAdOx1 nCoV-19 和 BNT162b2 同源和异源加强免疫的安全性、反应原性和免疫原性：一项前瞻性队列研究。
Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.
3
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
4
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.异源 ChAdOx1 nCoV-19/mRNA 疫苗接种的免疫原性和反应原性。
Nat Med. 2021 Sep;27(9):1530-1535. doi: 10.1038/s41591-021-01464-w. Epub 2021 Jul 26.
5
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.针对 SARS-CoV-2 的三种不同疫苗加强免疫后的抗体反应动力学。
Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.
6
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.预充间隔对同源和异源 COVID-19 疫苗接种方案的反应原性、免疫反应峰值和消退的影响：Com-COV 的探索性分析，一项随机对照试验。
Lancet Respir Med. 2022 Nov;10(11):1049-1060. doi: 10.1016/S2213-2600(22)00163-1. Epub 2022 Jun 9.
7
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.BNT162b2 或 mRNA-1273 异源加强接种后 SARS-CoV-2 IgA、IgG、中和和总抗体反应的随访和比较评估。
Influenza Other Respir Viruses. 2024 May;18(5):e13290. doi: 10.1111/irv.13290.
8
Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.细胞和体液免疫应答在异源和同源 SARS-CoV-2 疫苗接种中的相互关系。
Allergy. 2022 Aug;77(8):2381-2392. doi: 10.1111/all.15247. Epub 2022 Feb 16.
9
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.接种科兴新冠疫苗、腺病毒载体新冠疫苗和辉瑞疫苗加强针后对 SARS-CoV-2 变异株的免疫原性和反应原性：一项在泰国健康成年人中开展的开放标签随机研究。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. doi: 10.1080/21645515.2022.2091865. Epub 2022 Jul 11.
10
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.

引用本文的文献

1
Vaccination Strategies: Mixing Paths Versus Matching Tracks.疫苗接种策略：混合路径与匹配轨迹
Vaccines (Basel). 2025 Mar 13;13(3):308. doi: 10.3390/vaccines13030308.
2
Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis.新型mRNA疫苗可诱导强大的免疫原性，并提供抗结核病保护。
Front Immunol. 2025 Feb 13;16:1540359. doi: 10.3389/fimmu.2025.1540359. eCollection 2025.
3
Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.

本文引用的文献

1
Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses.延迟间隔 BNT162b2 mRNA COVID-19 疫苗接种可增强体液免疫并诱导强烈的 T 细胞反应。
Nat Immunol. 2022 Mar;23(3):380-385. doi: 10.1038/s41590-021-01126-6. Epub 2022 Feb 3.
2
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.巴西两剂科兴新冠疫苗（CoronaVac）既往接种者中异源与同源加强接种 COVID-19 疫苗（RHH-001）：一项四期、非劣效性、单盲、随机研究。
Lancet. 2022 Feb 5;399(10324):521-529. doi: 10.1016/S0140-6736(22)00094-0. Epub 2022 Jan 21.
3
同源/异源加强接种后不同新冠疫苗平台的体液免疫和细胞免疫持久性：接种后一年
Front Immunol. 2025 Jan 22;16:1526444. doi: 10.3389/fimmu.2025.1526444. eCollection 2025.
4
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial.一种改良型新冠mRNA疫苗SYS6006在健康成年人三剂灭活疫苗接种后作为第四剂加强针的安全性和免疫原性：一项开放标签的1期试验。
Life Metab. 2023 May 10;2(3):load019. doi: 10.1093/lifemeta/load019. eCollection 2023 Jun.
5
The Global Burden of Absenteeism Related to COVID-19 Vaccine Side Effects Among Healthcare Workers: A Systematic Review and Meta-Analysis.医护人员中与新冠疫苗副作用相关的缺勤全球负担：一项系统评价与荟萃分析
Vaccines (Basel). 2024 Oct 19;12(10):1196. doi: 10.3390/vaccines12101196.
6
Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?同源加强免疫6个月后，BNT162b2和mRNA-1273针对BA.1、BA.5和XBB.1.5（亚）变体的疫苗诱导体液反应：免疫原性是否等同？
Heliyon. 2024 Aug 10;10(16):e36116. doi: 10.1016/j.heliyon.2024.e36116. eCollection 2024 Aug 30.
7
Adaptive immune responses to two-dose COVID-19 vaccine series in healthy Canadian adults ≥ 50 years: a prospective, observational cohort study.健康的加拿大≥50 岁成年人两剂 COVID-19 疫苗系列的适应性免疫反应：一项前瞻性、观察性队列研究。
Sci Rep. 2024 Apr 18;14(1):8926. doi: 10.1038/s41598-024-59535-0.
8
SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals.二价 BA.4/5 新冠病毒疫苗接种后，既往感染和未感染个体的针对 SARS-CoV-2 的细胞和体液免疫。
Nat Commun. 2024 Apr 9;15(1):3077. doi: 10.1038/s41467-024-47429-8.
9
The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.针对基于载体或 RNA 的 SARS-CoV-2 疫苗的体液和细胞免疫反应的不同程度至少持续 18 个月，且与感染无关。
J Virol. 2024 Apr 16;98(4):e0191223. doi: 10.1128/jvi.01912-23. Epub 2024 Mar 19.
10
Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study.解读与新型冠状病毒2疫苗接种后严重不良事件相关的死亡：一项回顾性队列研究。
Vaccine X. 2024 Jan 20;16:100446. doi: 10.1016/j.jvacx.2024.100446. eCollection 2024 Jan.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
在英国（Com-COV2）进行的包含 mRNA、病毒载体和蛋白佐剂疫苗的异源 COVID-19 初级疫苗接种的免疫原性、安全性和反应原性：一项单盲、随机、2 期、非劣效性试验。
Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6.
4
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国，用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂（加强针）接种 7 种 COVID-19 疫苗的安全性和免疫原性（COV-BOOST）：一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
5
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.异源ChAdOx1 nCoV-19和mRNA序贯接种疫苗对瑞典有症状新冠病毒感染的有效性：一项全国性队列研究
Lancet Reg Health Eur. 2021 Dec;11:100249. doi: 10.1016/j.lanepe.2021.100249. Epub 2021 Oct 18.
6
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.
7
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients.在实体器官移植受者中，同源和异源mRNA及载体型新冠疫苗接种方案后，细胞免疫比体液免疫占优势。
Am J Transplant. 2021 Dec;21(12):3990-4002. doi: 10.1111/ajt.16818. Epub 2021 Sep 6.
8
Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination.异源和同源接种BNT162b2或ChAdOx1 nCoV-19疫苗后对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株的中和作用。
Cell Mol Immunol. 2021 Oct;18(10):2455-2456. doi: 10.1038/s41423-021-00755-z. Epub 2021 Aug 23.
9
Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.加拿大安大略省 BNT162b2 和 mRNA-1273 新冠病毒疫苗对有症状的 SARS-CoV-2 感染和严重新冠病毒感染结局的有效性：阴性检测设计研究。
BMJ. 2021 Aug 20;374:n1943. doi: 10.1136/bmj.n1943.
10
SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.异源接种ChAdOx1-S/BNT162b2疫苗后对SARS-CoV-2德尔塔变异株的中和作用
Lancet. 2021 Sep 18;398(10305):1041-1042. doi: 10.1016/S0140-6736(21)01891-2. Epub 2021 Aug 17.